相关实验视频
Updated: Aug 10, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
概括
需要高剂量胰岛素的患者通过较少的静脉注射胰岛素维持葡萄糖控制. 皮下组织可能会损害胰岛素吸收,可能导致胰岛素抵抗.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有高胰岛素需求的患者经常表现出显著的胰岛素耐药性.
- 传统的皮下胰岛素可能会受到可变的吸收.
- 了解替代胰岛素输送方法对于管理糖尿病至关重要.
研究的目的:
- 为了研究静脉注射胰岛素输注在患有高每日胰岛素需求的患者的疗效.
- 为了确定较小的静脉注射剂量是否可以保持足够的葡萄糖平衡,与高的皮下剂量相比.
- 探索与皮下吸收相关的胰岛素抵抗的潜在机制.
主要方法:
- 在6名患者中,静脉注射小剂量胰岛素 (50-63单位/天).
- 在整个研究期间监测葡萄糖平衡.
- 与患者之前的高胰岛素需求 (120-3000单位/天) 的比较.
主要成果:
- 所有六名患者都成功地保持了适当的葡萄糖平衡,而静脉注射胰岛素剂量较低.
- 静脉注射方案相比之前的皮下注射需要的胰岛素要少得多.
- 没有提到与静脉注射输液相关的不良事件.
结论:
- 静脉注射胰岛素输注可能是高胰岛素需求患者的有效替代方案.
- 皮下组织变化或吸收受损可能是导致胰岛素抵抗的因素.
- 需要进一步的研究来阐明皮下组织在胰岛素生物可用性和耐药性的作用.
相关概念视频
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Insipidus I: Introduction
Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...

